These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36398915)

  • 1. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients.
    Khairallah P; Robbins-Juarez S; Patel S; Shah V; Toma K; Fernandez H; Dube GK; King K; Mohan S; Husain SA; Morris H; Crew RJ
    Clin Transplant; 2023 Jan; 37(1):e14853. PubMed ID: 36398915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
    Streichart L; Felldin M; Ekberg J; Mjörnstedt L; Lindnér P; Lennerling A; Bröcker V; Mölne J; Holgersson J; Daenen K; Wennberg L; Lorant T; Baid-Agrawal S
    Trials; 2024 Mar; 25(1):213. PubMed ID: 38519988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients.
    Sangermano M; Negrisolo S; Antoniello B; Vadori M; Cozzi E; Benetti E
    Hum Immunol; 2024 Sep; 85(5):111088. PubMed ID: 39146803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
    Pearl M; Weng PL; Chen L; Dokras A; Pizzo H; Garrison J; Butler C; Zhang J; Reed EF; Kim IK; Choi J; Haas M; Zhang X; Vo A; Chambers ET; Ettenger R; Jordan S; Puliyanda D
    Clin Transplant; 2022 Aug; 36(8):e14734. PubMed ID: 35657013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes.
    Arrivé C; Bazzoli C; Jouve T; Noble J; Rostaing L; Stanke-Labesque F; Djerada Z
    BioDrugs; 2024 Sep; 38(5):703-716. PubMed ID: 39147956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopsy findings after detection of de novo donor-specific antibodies in renal transplant recipients: a single center experience.
    Waldecker CB; Zgoura P; Seibert FS; Gall S; Schenker P; Bauer F; Rohn B; Viebahn R; Babel N; Westhoff TH
    J Nephrol; 2021 Dec; 34(6):2017-2026. PubMed ID: 33866524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
    Boonpheng B; De Castro ICC; Ng YH; Blosser C; Bakthavatsalam R; Gimferrer I; Smith K; Leca N
    Clin Transplant; 2023 May; 37(5):e14936. PubMed ID: 36787372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
    Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
    Front Immunol; 2022; 13():839380. PubMed ID: 35493469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.
    Lavacca A; Presta R; Gai C; Mella A; Gallo E; Camussi G; Abbasciano I; Barreca A; Caorsi C; Fop F; Messina M; Rossetti M; Biancone L
    Clin Transplant; 2020 Aug; 34(8):e13908. PubMed ID: 32415711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
    Abuhelaiqa E; Friedlander R; Aull M; Putheti P; Sharma V; Suthanthiran M; Dadhania D
    Clin Transpl; 2016; 32():83-91. PubMed ID: 28564525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
    Doberer K; Duerr M; Halloran PF; Eskandary F; Budde K; Regele H; Reeve J; Borski A; Kozakowski N; Reindl-Schwaighofer R; Waiser J; Lachmann N; Schranz S; Firbas C; Mühlbacher J; Gelbenegger G; Perkmann T; Wahrmann M; Kainz A; Ristl R; Halleck F; Bond G; Chong E; Jilma B; Böhmig GA
    J Am Soc Nephrol; 2021 Mar; 32(3):708-722. PubMed ID: 33443079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
    Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
    Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
    Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
    Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy.
    Chamoun B; Sánchez-Sancho P; Torres IB; Gabaldon A; Perelló M; Sellarés J; Moreso F; Serón D
    Nefrologia (Engl Ed); 2022; 42(5):578-584. PubMed ID: 36717307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.